Skip to main content
AmigoFish

DNA Today: A Genetics Podcast

Kira Dineen, Gene Pool MediaAudio

Format:
Podcast
New episodes:
Weekly
Typical length:
about 35 minutes
Latest episode:
Not rated yet
CosmosOpen at the sourceReport a problemIs this your show? Get a badge

About this show

Discover New Advances in the world of genetics, from technology like CRISPR to rare diseases to new research. For 14 years, multi-award winning podcast ”DNA Today” has brought you the voices of leaders in genetics. Host Kira Dineen brings her genetics expertise to interview geneticists, genetic counselors, patient advocates, biotech leaders, researchers, and more.

***Best Science and Medicine Podcast Award Winner (2020, 2021 and 2022)***

Learn more (and stream all 400+ episodes) at DNAtoday.com. You can contact the show at info@DNAtoday.com.

This show is part of "Gene Pool Media: The Science Podcast Network" head to GenePoolMedia.com (http://GenePoolMedia.com) to explore all our science themed shows.

Covers: genetics, genetic testing, rare diseases, crispr gene editing, genetic counseling, prenatal screening, cancer genetics, inherited conditions

Show details and episodes come from the publisher's public feed at feed.podbean.com. Last updated . Names, artwork and text belong to their publishers.

Recently on this show

Summary of recent episodes, drawn from the publisher's feed.

DNA Today is a podcast where host Kira Dineen interviews people working in genetics, including geneticists, genetic counselors and patient advocates, about new research and technologies. Recent episodes cover whole genome sequencing, optical genome mapping, personalized CRISPR treatment, and achondroplasia treatment advances.

Report a problem with this summary

Cosmos

Similar in subject

See the full Cosmos

Similar shows

See all Education shows

Explore more

Episodes

  • #420 NSGC 2026: Ambry's Whole Genome Sequencing and BillionToOne's Unity Confirm

    · 31 min

    In this episode, we're coming to you from Baltimore for the National Society of Genetic Counselors (NSGC) 2026 Annual Conference! From new approaches to whole genome sequencing to the ability to analyze intact fetal cells through a pregnant person’s blood sample, we're exploring two exciting advances in genetic testing that could change how patients receive answers. Host Kira Dineen sits down with experts from Ambry Genetics and BillionToOne to discuss new technologies unveiled at the conference, their clinical applications, and how they could improve diagnostic accuracy and accessibility. We also celebrate Genetic Counselor Appreciation Day, highlight memorable moments from NSGC 2026, and share a special thank-you following Kira's recognition with the NSGC Leader in Community Engagement Award! Featured Guests Thomas "TJ" Slavin Jr., MD, is the Chief Medical Officer of Ambry Genetics and a medical geneticist. He joins us to discuss Ambry Genetics' newly launched whole genome sequencing offerings, GenomeNext and GenomeReveal, and how integrating RNA analysis, pangenome references, and proactive reanalysis could help end the diagnostic odyssey for more families. Jennifer "Jen" Hoskovec, MS, CGC, is Vice President of Medical Affairs at BillionToOne and a past president of NSGC (2014). She returns to DNA Today to introduce Unity Confirm, a new prenatal testing option that isolates and sequences intact circulating placental cells from a pregnant person’s blood to provide additional information following high-risk NIPT results. In This Episode We Discuss Ambry Genetics: Whole Genome Sequencing, RNA Analysis, and the Pangenome - How Tempus' acquisition of Ambry Genetics brings together tumor sequencing and germline testing capabilities. - Why Ambry chose 2026 to launch GenomeNext and GenomeReveal and how whole genome sequencing is changing rare disease diagnostics. - How RNA analysis can help clarify variants of uncertain significance (VUS), particularly variants that may affect RNA splicing. - Why incorporating a human pangenome reference can improve variant detection across diverse ancestral populations and help address disparities in genetic testing. - How Ambry's Patient for Life program proactively reanalyzes genetic data and contacts providers when new evidence leads to clinically meaningful changes. - Why identifying dual genetic diagnoses is increasingly important and how ongoing reanalysis can reveal additional explanations for a patient's symptoms. Clarification - Dr. Salvin mentioned Tempus is "the largest tumor sequencing company", it’s important to note that this is in the context of comprehensive genomic profiling (CGP). BillionToOne: Unity Confirm and Cell-Based Prenatal Testing - How Unity Confirm differs from traditional cell-free DNA screening by isolating intact circulating extravillous trophoblasts from a pregnant person’s blood. - How sequencing individual placental cells can provide additional information following a high-risk NIPT result. - Why Unity Confirm is positioned as an additional testing option rather than a replacement for diagnostic procedures such as chorionic villus sampling (CVS) or amniocentesis. - How this technology could help patients who decline invasive testing or face geographic, financial, or gestational-age barriers to accessing diagnostic procedures. - The limitations of analyzing a small number of cells, particularly when considering placental mosaicism and conditions such as Turner syndrome. - How staining techniques and genetic comparisons help distinguish placental trophoblasts from maternal white blood cells. - How genetic counselors can integrate another source of prenatal information into patient-centered conversations about screening, diagnosis, and reproductive decision-making. Resources & Links NSGC Annual Conference National Society of Genetic Counselors (NSGC) (https://www.nsgc.org) – Learn more about NSGC, its annual conference, and resources for…

    Not rated yet
  • #419 Optical Genome Mapping and Long-Read Sequencing: Unlocking Rare Diagnoses

    · 39 min

    What happens when traditional genetic testing leaves patients and families without answers? Emerging technologies like optical genome mapping (OGM) and long-read sequencing are expanding what laboratories can detect, from complex structural variants to difficult-to-analyze repetitive regions of the genome. These advances are already changing clinical testing strategies and helping uncover diagnoses that previously remained out of reach. In this episode, we welcome back Dr. Nikhil Sahajpal, Assistant Laboratory Director at Greenwood Genetic Center (GGC), who previously joined us in Episode 362 (https://dnapodcast.com/episodes/2025/10/10/362-optical-genome-mapping-detecting-structural-variants-missed-by-traditional-tests) to introduce optical genome mapping. Now, nearly two years after GGC began offering OGM clinically, Dr. Sahajpal shares how the technology is being integrated into rare disease diagnostics, including additional diagnostic findings in at least 5% of previously unsolved cases. The conversation takes a closer look at facioscapulohumeral muscular dystrophy (FSHD), a genetically complex condition involving D4Z4 repeat contractions, epigenetic changes, and inappropriate DUX4 expression. Dr. Sahajpal explains how OGM and short-read sequencing can work together to distinguish FSHD1 from FSHD2, and why the laboratory is evaluating long-read sequencing as a potential way to streamline this testing. We also explore targeted applications of OGM and long-read sequencing, including clarifying DMD duplications, mapping structural variant breakpoints, and determining whether variants are in cis or trans. Finally, Dr. Sahajpal discusses where long-read genome sequencing fits into the rare disease diagnostic workflow and whether a more comprehensive, unified genetic test could eventually reduce the need for multiple testing platforms. Episode Discussion Topics - How optical genome mapping compares with karyotyping, FISH, and chromosomal microarray - Greenwood Genetic Center's clinical experience with OGM and its additional diagnostic yield in previously unsolved rare disease cases - When OGM may serve as a reflex test following negative genome sequencing - The genetics of FSHD1, including D4Z4 repeat contractions, permissive haplotypes, and DUX4 expression - Why chromosome 4 and chromosome 10 repeat regions complicate FSHD testing - How OGM and short-read sequencing contribute to distinguishing FSHD1 and FSHD2 - The potential for long-read sequencing to assess repeat size, sequence variants, and DNA methylation - When long-read genome sequencing may be appropriate for patients with broad or nonspecific phenotypes - How targeted OGM can clarify DMD duplications and change carrier screening interpretation - Using targeted long-read sequencing to phase variants in recessive conditions without parental samples - The limitations of phenotype-driven variant analysis and the future of comprehensive genomic testing Resources & Links - Greenwood Genetic Center (https://ggc.org/) - OGM Complete (https://ggc.org/tests/optical-genome-mapping-complete/) - OGM Targeted (https://ggc.org/tests/optical-genome-mapping-targeted/) - Facioscapulohumeral Muscular Dystrophy Type 2 (FSHD2) NGS Panel (https://ggc.org/tests/facioscapulohumeral-muscular-dystrophy-type-2-fshd2-ngs-panel/) - FSHD1 (https://ggc.org/tests/optical-genome-mapping-fshd1/) - Long-read Sequencing-Trio Analysis (https://ggc.org/tests/optical-genome-mapping-fshd1/) - Long-read Sequencing-Targeted Analysis (https://ggc.org/tests/long-read-sequencing-targeted-analysis/) - Sahajpal Completes Laboratory Fellowship at GGC and Joins Faculty (https://ggc.org/sahajpal-completes-laboratory-fellowship-at-ggc-and-joins-faculty/) - Sahajpal NS, Mondal AK, Singh H, Vashisht A, Ananth S, Saul D, Hastie AR, Hilton B, DuPont BR, Savage NM, Kota V, Chaubey A, Cortes JE, Kolhe R. Clinical Utility of Optical Genome Mapping and 523-Gene Next Generation Sequencing Panel for…

    Not rated yet
  • #418 Hypophosphatasia Genetics: One Gene, Many Presentations

    · 34 min

    How can variants in the same gene cause life-threatening disease in infancy for some individuals, while others experience mild symptoms or remain asymptomatic? Hypophosphatasia (HPP) challenges traditional expectations about genetic inheritance, with both autosomal dominant and autosomal recessive forms and a remarkably broad spectrum of clinical presentations. In this episode, recorded in person in Nashville, our guest is Dr. Kathryn Dahir, Professor of Medicine in the Division of Diabetes, Endocrinology, and Metabolism at Vanderbilt University Medical Center and Director of the Program for Metabolic Bone Disorders. Drawing on decades of experience caring for patients with rare skeletal conditions, Dr. Dahir explores the complex genetics of HPP and why understanding a patient's clinical presentation is just as important as interpreting their genetic test results. The conversation begins with a patient case that challenged Dr. Dahir's understanding of HPP. Initially treated for osteoporosis, the patient experienced recurrent fractures and worsening symptoms despite treatment. Further investigation revealed impaired bone mineralization, low alkaline phosphatase (ALP), and a single ALPL variant, illustrating how individuals with one affected copy of the gene can experience significant disease. Dr. Dahir explains how the ALPL gene encodes tissue-nonspecific alkaline phosphatase (TNSALP), an enzyme essential for healthy bone mineralization, and how disruption of its activity contributes to the manifestations of HPP. We explore the differences between autosomal dominant and autosomal recessive inheritance, the challenges of predicting disease severity from genetic testing alone, and why even relatives carrying the same ALPL variant may have very different symptoms. Dr. Dahir discusses the importance of identifying variants in cis or trans, recognizing deletions and duplications, evaluating variants of uncertain significance, and considering how genetic modifiers, environmental exposures, and coexisting conditions can influence a patient's presentation. Finally, we discuss the evolving landscape of HPP genetic testing, including the importance of longitudinal follow-up, resources such as the global ALPL variant database, and ongoing efforts to improve variant classification. As genomic testing becomes increasingly accessible, this conversation highlights both its potential to improve rare disease diagnosis and the limitations of using genetics alone to predict an individual's future health. Episode Discussion Topics - Dr. Dahir's clinical experience treating HPP and other rare metabolic bone disorders at Vanderbilt University Medical Center - Why genetic testing must be interpreted alongside clinical symptoms, biochemical findings, and patient history - A patient case illustrating how HPP can be mistaken for osteoporosis and why low alkaline phosphatase is an important diagnostic clue - How the ALPL gene and tissue-nonspecific alkaline phosphatase (TNSALP) regulate bone mineralization - The differences between autosomal dominant and autosomal recessive HPP and the challenges of distinguishing affected individuals from asymptomatic carriers - Why genotype-phenotype correlations in HPP are complex, even among family members with the same genetic variant - The importance of determining whether variants are in cis or trans and identifying deletions or duplications that some testing platforms may miss - How modifier genes, epigenetics, medication exposures, and coexisting medical conditions may influence HPP symptoms and severity - Interpreting variants of uncertain significance and the importance of genetic counseling, variant reclassification, and long-term follow-up - The role of the global ALPL variant database in improving classification and understanding the clinical significance of genetic variants - Future opportunities to identify protective genetic factors and improve predictions of disease progression About…

    Not rated yet
  • #417 ASHG 2026: Electronic Genome Mapping, AI in Genetics, & the Future of Research

    · 41 min

    For the third year in a row, DNA Today is bringing you inside the American Society of Human Genetics (ASHG) Annual Meeting, and this year, we've taken our genetics coverage international! We're reporting from beautiful Montréal, Canada, where thousands of geneticists, researchers, clinicians, and industry leaders gathered to share the latest breakthroughs shaping the future of genomics. From cutting-edge technologies to big questions about the future of genetic medicine, there's no shortage of exciting science to unpack. And don't worry, we're bringing you all the highlights, no passport required, eh? In this episode, host Kira Dineen takes you behind the scenes of ASHG 2026 through two special segments recorded at the conference. First, we stop by the Nabsys booth to chat with Founder and CEO Barrett Bready, MD, about how Electronic Genome Mapping (EGM) is advancing our ability to detect structural variants. We explore how the technology compares with traditional approaches, its emerging applications in hematologic malignancies, and the latest research Nabsys is showcasing at ASHG. For our second segment, we're live on location! DNA Today teamed up with Wiley's Advanced Portfolio to co-host a special brunch featuring a live podcast recording right from the conference. With breakfast on the table and big questions on the menu, Kira moderated a conversation with leading genetics researchers and publishing experts about the discoveries, challenges, and opportunities shaping the field. From translating genetic findings into new therapies and harnessing AI to accelerate research to fostering interdisciplinary collaboration and rethinking the role of scientific publishing, this discussion goes beyond the conference presentations to explore where genetics is headed next. Whether you joined us in Montréal or are experiencing the conference from afar, consider this your front-row seat to some of the conversations shaping the future of genetics. We're serving up fresh science with a side of maple syrup, because when it comes to genetics, there's always more to discover, eh? Nabsys Segment Guest Barrett Bready, MD (https://www.linkedin.com/in/barrett-bready-52b4837/) is Founder and CEO of Nabsys. He is passionate about the impact that advanced technology can have on the understanding of disease as well as on its diagnosis and treatment. He has raised $150 million to realize a new way of analyzing DNA that uses proprietary solid-state electronic nanodetectors to analyze very long molecules, with an initial focus on genomic structural variation. Barrett is an adjunct professor at Brown University where he lectures on the rapidly evolving business of life sciences. He serves as a commissioner of the I-195 Redevelopment District Commission, a major land redevelopment initiative in downtown Providence, RI with a focus on life sciences and other high-technology sectors. He has received numerous awards including, in 2011, Rhode Island Innovator of the Year, and in 2018, a career achievement award from the Warren Alpert Medical School of Brown University. Barrett graduated from the highly competitive Program in Liberal Medical Education (PLME) at Brown University where he received an M.D. and an Sc.B. in Physics and won the undergraduate physics award (the Lindsay Prize) and the Galletti Prize for physics in medicine. Nabsys Discussion Topics - ASHG 2026 conference highlights and a presentation on electronic genome mapping (EGM) in hematologic malignancies - Why genomic structural variants matter in cancer and rare disease - How traditional sequencing and cytogenetic approaches may leave gaps in detecting structural variation - Nabsys’ electronic genome mapping as a high-resolution, top-down approach to studying genome structure - How EGM uses electrical detection to read sequence-specific tags on long DNA molecules - Identifying deletions, insertions, inversions, and translocations by comparing tag patterns - How EGM relates to…

    Not rated yet
  • #416 How Baby KJ Became the First Patient Treated With Personalized CRISPR

    · 29 min

    CRISPR has carried enormous promise since scientists first realized its potential to edit the human genome, but it has also raised some of the biggest ethical questions in modern genetics. In this episode, Kira Dineen sits down with Dr. Kiran Musunuru to trace the evolution of human gene editing, beginning with the controversial 2018 announcement that scientist He Jiankui had used CRISPR to edit human embryos in China, resulting in the birth of the world’s first gene-edited babies. The experiment, which targeted the CCR5 gene in an attempt to reduce susceptibility to HIV, sparked international condemnation and intensified debate over germline genome editing, where genetic changes could potentially be passed on to future generations. From there, the conversation shifts to a dramatically different application of CRISPR: treating serious genetic disease in an individual patient. Dr. Musunuru shares the remarkable story of Baby KJ, who was born with severe carbamoyl phosphate synthetase 1 (CPS1) deficiency and became the first patient to receive a personalized CRISPR-based therapy designed specifically for his genetic variant. The team developed KJ’s customized base-editing treatment in approximately six months, moving from identification of his variant through preclinical testing, manufacturing, regulatory review, and ultimately treatment. Dr. Musunuru explains how KJ’s therapy works, what researchers have learned from his response so far, and whether his case could establish a new pathway for treating patients with ultra-rare genetic conditions who may never fit into a traditional drug-development model. This interview was recorded in person at AGBT Precision Health in Coronado, California, we caught up with Dr. Musunuru after a presentation. Episode Discussion Topics: - The 2018 announcement of the world’s first CRISPR-edited babies in China - Why He Jiankui’s experiment targeting the CCR5 gene sparked global scientific and ethical backlash - The difference between editing embryos and germline cells versus editing somatic cells in a patient - What the CRISPR babies controversy taught the scientific community about oversight, regulation, and responsible use of gene-editing technology - How the field of CRISPR medicine has evolved since 2018 - How naturally occurring PCSK9 variants helped reveal a powerful target for lowering LDL cholesterol and preventing cardiovascular disease - Using CRISPR base editing to permanently turn down PCSK9 activity in the liver as a potential one-time treatment for high cholesterol - The development of PCSK9 gene-editing therapies for patients with familial hypercholesterolemia and premature coronary artery disease - The possibility of moving cardiovascular care from lifelong medications to durable, one-time genetic treatments - How cardiovascular gene editing helped pave the way for applying similar base-editing technology to rare diseases like Baby KJ’s CPS1 deficiency - What CPS1 deficiency is and why it can become life-threatening shortly after birth - How Baby KJ’s diagnosis created an opportunity to pursue a personalized gene-editing treatment - Why KJ’s specific genetic variant was a candidate for base editing - How base editing differs from traditional CRISPR approaches that make double-stranded breaks in DNA - Developing a gene-editing therapy specifically for a single patient - Delivering the gene editor to liver cells using lipid nanoparticles - Why the liver is an especially promising target for in vivo gene-editing therapies - The collaboration between researchers, clinicians, biotechnology companies, regulators, and KJ’s family that made the treatment possible - Navigating FDA review for a therapy that had never previously been given to a human - Why KJ received multiple doses of the therapy - Early signs that the treatment was having an effect, including increased dietary protein tolerance and reduced dependence on nitrogen-scavenging medication - Why…

    Not rated yet
  • #415 Achondroplasia Treatment Advances with Dr. Ravi Savarirayan

    · 1 min

    Please note this episode is only available on our website, DNAToday.com under Episode 415 (https://dnapodcast.com/episodes/2026/10/9/415-achondroplasia-treatment-advances-with-dr-ravi-savarirayan%20), and access is limited to those in the United States. In just a few years, achondroplasia treatment has expanded from no approved precision medicines to multiple approaches targeting the condition’s underlying biology. In this episode, we continue our conversation with Dr. Ravi Savarirayan, a global leader in skeletal dysplasia care and a lead investigator across multiple achondroplasia clinical development programs. Dr. Savarirayan previously joined us on Episode 401 (https://dnapodcast.com/episodes/2026/7/3/401-the-first-precision-medicine-for-achondroplasia-with-dr-ravi-savarirayan), where we explored the first approved precision treatment for achondroplasia and international guidance for its use. This time, we take a broader look at the rapidly evolving achondroplasia treatment landscape, including how different therapeutic approaches target FGFR3 signaling, how researchers interpret clinical trial outcomes, and what results from the Phase 3 PROPEL 3 study of investigational infigratinib could mean for children and families. We also discuss why treatments cannot be reliably compared using results from separate clinical trials, the importance of studying outcomes beyond growth, and the questions that remain about long-term safety, functional benefits, treatment selection, and switching therapies. Thank you to BridgeBio for sponsoring this episode. Episode Discussion Topics - How the achondroplasia treatment landscape has evolved in the last seven years - How achondroplasia affects more than height - How current and investigational therapies target FGFR3 signaling in different ways - What annualized growth velocity, height Z-scores, and body proportionality reveal in clinical trials - Key findings from the Phase 3 PROPEL 3 study of investigational infigratinib - What researchers can and cannot yet predict about final adult height based on current data - Why body proportionality may be an important clinical and functional outcome - How researchers are evaluating potential effects on mobility, reach, independence, and daily activities - The long-term safety questions that remain when treatment begins in childhood - Why results from separate achondroplasia trials should not be compared directly - How families and healthcare providers can weigh treatment benefits, risks, administration, and personal goals - What is being studied in hypochondroplasia and other conditions involving overactive FGFR3 signaling Our Guest: Dr. Ravi Savarirayan Ravi Savarirayan is consultant clinical geneticist at Victorian Clinical Genetics Services, Professorial fellow at the University of Melbourne, and Group leader (Molecular Therapies at Murdoch Children’s Research Institute, Victoria, Australia. Professor Savarirayan received his MBBS from the University of Adelaide, Australia in 1990 and became a Fellow of the Royal Australasian College of Physicians in 1997. He was certified as a specialist in Clinical Genetics by the Human Genetics Society of Australasia in 1998 and was awarded his Doctor of Medicine from the University of Melbourne in 2004. He was awarded the Fulbright Professional Scholarship for Australia in 1998, and took this up at University of California, Los Angeles (UCLA). Professor Savarirayan’s primary research focus is on inherited disorders of the skeleton causing short stature, arthritis, and osteoporosis. He has published over 230 peer-reviewed articles and received over $35M in research funding, collaborating with researchers from 40 countries. His current clinical trial activities are pioneering disruptive new therapies for the treatment of genetic disorders. He was the global lead investigator of the clinical development program that identified vosoritide as the first precision therapy for children with…

    Not rated yet
  • #414 How To Find Genetics Professionals Worldwide: The Global Genetics Directory

    · 27 min

    When patients relocate or relatives living abroad need cascade testing, finding a qualified genetics professional in another country can be surprisingly difficult. The new Global Genetics Directory aims to change that through a free, verified, peer-to-peer resource connecting genetics and genomics professionals worldwide. In this episode of DNA Today, recorded in person at our studio, host Kira Dineen is joined by genetic counselor Monisha Sebastin, Founder and Principal Investigator of the Global Genetics Directory. Monisha explains how her international background and leadership within the genetics community revealed the need for a centralized global resource. We explore how the directory was developed with support from the prestigious Audrey Heimler Special Projects Award, how professionals are verified across different credentialing systems, and why the team chose a closed, consent-based model rather than a publicly searchable directory. Monisha also shares how the directory could strengthen cross-border patient care, cascade testing, professional collaboration, and access to genetics services around the world. Episode Discussion Topics - Why finding genetics professionals in other countries can be challenging - How Monisha’s experiences in India and the United States shaped her perspective on global access - When international connections are especially important for patient care and cascade testing - What genetics professionals around the world said they needed from a global directory - How NSGC’s Audrey Heimler Special Projects Award supported the project - How registration, credential verification, and directory searches work - Why eligibility is limited to credentialed genetics and genomics professionals - How the directory accommodates differences in professional titles, credentials, and scopes of practice - Why membership is free - The benefits of a closed, peer-to-peer, and consent-based model - How patients seeking care abroad can work with their current providers - The team’s vision for expanding the directory and strengthening international collaboration About Monisha Sebastin Monisha Sebastin, MS, LCGC, is the Founder and Principal Investigator of the Global Genetics Directory. She is also a senior pediatric genetic counselor in New York City, where she specializes in cardiogenetics and research. Monisha grew up in India and earned her undergraduate degree in genetic engineering before completing her genetic counseling training at Sarah Lawrence College. Her international background, clinical experience, and leadership within the global genetic counseling community helped inspire the development of the Global Genetics Directory. The directory was developed with support from the Audrey Heimler Special Projects Award for Monisha’s project, “Evaluating International Genomics Providers’ Needs and Perspectives on a Global Genomics Services Directory.” Resources & Links - Global Genetics Directory (https://www.globalgeneticsdirectory.org/) - To email directly, contact@globalgeneticsdirectory.com - National Society of Genetic Counselors (NSGC) (https://www.nsgc.org/) - NSGC’s Audrey Heimler Special Projects Award (https://www.nsgc.org/About/Awards-Grants/AHSPA) - Find A Genetic Counselor Directory (https://findageneticcounselor.nsgc.org/) Relevant DNA Today Podcast Episodes - #109 Shenela Lakhani on Genetic Counseling in Qatar (https://dnapodcast.com/episodes/2019/9/28/109-shenela-lakhani-on-genetic-counseling-in-qatar) — Hear from Qatar’s first certified genetic counselor about establishing the profession in a new country and adapting counseling across cultures. - #110 Gattaca, 22 Years Later with Catherine Mayo and Ale Cantu (https://dnapodcast.com/episodes/2019/10/23/110-gattaca-22-years-later) — Catherine Mayo’s first DNA Today appearance examines the film’s enduring relevance to genetic counseling, reproductive decision-making, and genetic discrimination. - #114 Matt Burgess on…

    Not rated yet
  • #413 PKU Beyond the Diet: Food, Mental Health, and Daily Life

    · 36 min

    For most people, eating is an ordinary part of the day. But when you have phenylketonuria (PKU), every meal can involve calculations, preparation, medical monitoring, and decisions that affect how your brain and body feel. This is DNA Today, a podcast from Gene Pool Media, where we explore the breakthroughs, challenges, and human impact of genetics and genomics. I’m your host Kira Dineen, a genetic counselor and award-winning science podcaster and speaker. This is a continuation of our PKU series, sponsored by PTC Therapeutics. In the first episode (Episode 399), we explored how PKU helped launch newborn screening and why early diagnosis can completely change a child’s future. In this second episode, we’re looking at what comes next: what it actually means to manage PKU through food, and how this affects school, friendships, celebrations, mental health, independence, and a person’s relationship with food. Joining us are a mother and daughter who have experienced that journey together: Dr. Jennifer Brown is a geneticist, science communicator, and author of When the Baby Is Not OK: Hopes & Genes, a wonderful memoir about genetics, motherhood, and raising children with PKU. Lillian Isabella is a playwright, advocate, and graduate student in Columbia University's Narrative Medicine program who served six years on the National PKU Alliance board and lives with PKU. She is Dr. Brown's daughter. Our guests are participating in this podcast to share their experience and opinions only. They are not providing any medical advice. Always check with your healthcare provider for treatment and screening advice. Episode Discussion Topics - What a “low-protein diet” actually requires for someone living with PKU - How protein and phenylalanine tolerance are determined and monitored over time - The work involved in grocery shopping, measuring food, reading labels, preparing specialized meals, and ordering medical foods - Dr. Brown’s experience learning to treat feeding her newborn as a form of medical care - Raising two daughters with PKU and balancing dietary management with everyday family life - Lillian’s relationship with PKU formula and medical shakes throughout different stages of life - How elevated phenylalanine levels can affect focus, energy, mood, and daily functioning - Navigating school, birthday parties, holidays, camps, travel, dating, and other food-centered social situations - When Lillian first became aware that she ate differently from her peers - How constant food monitoring can influence a person’s emotional relationship with eating - PKU-related frustration, burnout, anxiety, guilt, and resentment - How language used by clinicians can shape a child’s identity and relationship with their condition - Transitioning from parent-managed PKU care to greater independence in adolescence and adulthood - Returning to metabolic care after time away - Lillian’s experience turning her lived experience with PKU into advocacy - Advice for parents who have just learned their baby has PKU - How guidance and support may change through early childhood, adolescence, and adulthood - Dr. Brown and Lillian’s hopes for the future of PKU care and what could make everyday management easier Resources & Links - When the Baby Is Not OK: Hopes & Genes (https://www.goodreads.com/book/show/223703166-when-the-baby-is-not-ok) by Dr. Jennifer Brown - PKU / Phenylketonuria (https://www.ptcbio.com/therapeutic-areas/phenylketonuria/) - Phenylalanine hydroxylase deficiency ACT Sheet (https://www.ncbi.nlm.nih.gov/books/NBK55827/bin/Phenylalanine.pdf) - The Newborn Screening Information Center (NBSIC) (https://newbornscreening.hrsa.gov/) - Recommended Uniform Screening Panel, or RUSP (https://www.hrsa.gov/advisory-committees/heritable-disorders/rusp) - RUSP overview for families (https://newbornscreening.hrsa.gov/about-newborn-screening/recommended-uniform-screening-panel) - ACMG Newborn Screening ACT Sheets and Algorithms…

    Not rated yet
  • #412 How Prenatal cfDNA Can Uncover Undiagnosed Maternal Cancer

    · 36 min

    Prenatal cell-free DNA screening is designed to assess a pregnancy for chromosome conditions; but in rare cases, it can reveal something entirely unexpected about the pregnant patient’s own health. In this episode, Kira Dineen is joined in-person by Dr. Diana Bianchi to explore how unusual or non-reportable cfDNA screening results can sometimes be a signal of an undiagnosed maternal cancer. Dr. Bianchi shares findings from the NIH’s ongoing IDENTIFY study, which is investigating why these unexpected cfDNA patterns occur, how clinicians can distinguish potential malignancy from other explanations, and what should happen next when a prenatal screening result raises concern about maternal cancer. We recorded this episode in person at AGBT Precision Health, one of our favorite conferences of the year. The conference wrapped this past Wednesday and brought together leaders across genomics, precision medicine, research, and clinical care in an intimate setting that makes it easy to connect, learn, and have thoughtful conversations. The conference is also hosted at a beautiful resort in the San Diego area, which makes the experience especially memorable. We highly recommend attending next year’s AGBT Precision Health meeting, taking place September 13–15, 2027 (https://www.agbtprecisionhealth.org/), at the same gorgeous location. We already put it on our calendars! In This Episode, We Discuss: - What “non-reportable” or “uninterpretable” cfDNA results actually mean - How unusual cfDNA results differ from typical test failures - Determining whether an unexpected cfDNA signal originates from the fetus, placenta, or pregnant patient - Maternal causes of discordant cfDNA results, including fibroids, clonal hematopoiesis, a demised twin, and malignancy - Why tumors can release DNA into the bloodstream that is detected during prenatal screening - Why Dr. Bianchi and her colleagues launched the prospective IDENTIFY study in 2019 - What participants undergo when they travel to the NIH Clinical Center for evaluation - Results from the first 107 IDENTIFY participants, including the 52 participants diagnosed with cancer - Why lymphoma is frequently identified through these unusual cfDNA patterns - Chromosomal patterns that are particularly suspicious for malignancy - Why gains and losses involving three or more chromosomes can be an important warning sign - Why symptoms, physical examinations, and routine bloodwork may not reliably identify patients with occult cancer - The role of rapid whole-body MRI in evaluating patients for malignancy - Approaches clinicians can consider when whole-body MRI is not readily available - Diagnosing and treating cancer during pregnancy - What researchers have learned from participants whose evaluation does not identify cancer - How the IDENTIFY study has expanded since its original published cohort - How laboratories should report cfDNA patterns that may suggest maternal malignancy - The need for professional society guidelines for clinicians receiving these unusual results - What genetic counselors, OB/GYNs, and maternal-fetal medicine specialists should do when they receive a concerning non-reportable NIPS result About Dr. Diana Bianchi Diana W. Bianchi, MD (https://www.linkedin.com/in/diana-w-bianchi-md/), is a physician-scientist and a pioneer in noninvasive prenatal genetic testing and fetal cell microchimerism research. She previously served as Director of the Eunice Kennedy Shriver National Institute of Child Health and Human Development at the National Institutes of Health and was a senior investigator in the Center for Precision Health Research at the National Human Genome Research Institute. Her research has helped define how prenatal cell-free DNA sequencing can unexpectedly identify genomic patterns associated with maternal malignancy. In 2019, Dr. Bianchi and colleagues launched the IDENTIFY Study — Incidental Detection of Maternal Neoplasia Through Non-Invasive…

    Not rated yet
  • #411 Mock Cancer Genetic Counseling Session: Colon Cancer and Lynch Syndrome

    · 30 min

    What happens during genetic counseling after someone develops colon cancer at a young age and their tumor testing raises concern for Lynch syndrome? This is the eighth installment in our Mock Genetic Counseling Session Series! In this episode, cancer genetic counselor Connor Linehan and genetic counseling student Edith Atwerebour perform a mock cancer genetic counseling session. Edith plays Patricia, a 42-year-old woman recently diagnosed with Stage I colon cancer whose tumor showed loss of the MSH2 and MSH6 proteins. Although this tumor result raises suspicion for Lynch syndrome, it does not confirm that Patricia has an inherited cancer predisposition. Through this simulated session, Connor explains the difference between tumor and germline testing, reviews the pattern of cancer in Patricia’s family, and discusses how genetic testing could inform her future medical care and clarify cancer risks for her relatives. Patricia is particularly concerned about her kids. The session demonstrates how genetic counselors address the emotional impact of a possible hereditary cancer condition while explaining why testing and cancer screening are generally not recommended for children when the associated risks begin in adulthood. Previous installments of this series have explored prenatal, pediatric, cardiovascular, cancer, and teratogen genetic counseling. We hope these sessions help prospective and current genetic counseling students, and the general public, better understand what happens during a genetic counseling appointment. The Actors Connor Linehan, MS, LCGC is a board-certified genetic counselor in Connecticut specializing in cancer. He helps patients and families understand inherited cancer risks, genetic testing options, and how test results may affect medical management and relatives. He is also a Clinical Instructor at a genetic counseling graduate program. Connor is the President of The Connecticut Genetic Counselor Association (http://ctgca.org). (Fun fact, our host Kira Dineen designed this new website!) Edith Atwerebour, MPH (https://www.linkedin.com/in/edithatwerebour/) is currently a student in the Human Genetics Program at Sarah Lawrence College training to become a genetic counselor. In this mock session, she plays Patricia, a 42-year-old woman recently diagnosed with Stage I colon cancer whose abnormal tumor testing raises concern for Lynch syndrome. The premise of this mock case was developed as part of Atwerebour’s internship with DNA Today. Edith also appeared in the previous installment of this series,#406 Mock Teratogen Genetic Counseling Session: Ozempic, Zoloft, Xanax, and Metformin (https://dnapodcast.com/episodes/2026/8/7/406-mock-teratogen-genetic-counseling-session-ozempic-zoloft-xanax-and-metformin), in which she played Denise, a pregnant patient seeking information about several medication exposures. Mock Session Overview - Establishing the purpose and structure of a cancer genetic counseling appointment - Reviewing Patricia’s colon cancer diagnosis, treatment, and current health - Addressing Patricia’s concerns about her children early in the session - Constructing and evaluating a three-generation cancer family history - Identifying features that raise concern for hereditary cancer, including colon cancer before age 50 and multiple Lynch-associated cancers - Explaining how genes normally help protect the body from developing cancer - Sporadic, familial, and hereditary explanations for cancer - The function of the mismatch repair genes MLH1, MSH2, MSH6, and PMS2 - How immunohistochemistry evaluates mismatch repair protein expression in a tumor - Why loss of MSH2 and MSH6 raises concern for mutations (pathogenic variants) in cancer genes - The difference between tumor testing and germline genetic testing - Why abnormal tumor testing does not independently establish a Lynch syndrome diagnosis - How genetic changes confined to a tumor differ from inherited germline variants - Why…

    Not rated yet
  • #410 Gypsy Rose Blanchard’s 1q21.1 Microdeletion: What Does It Explain?

    · 43 min

    This episode drop from the PRETEND podcast series “The Gypsy Rose Obsession” features Kira Dineen explaining what Gypsy Rose Blanchard’s genetic test result may, and may not, mean. Gypsy Rose Blanchard’s medical history has been scrutinized for years. Throughout her childhood, her mother, Dee Dee Blanchard, presented her as having numerous serious medical conditions, resulting in medications, procedures, mobility aids, and countless medical appointments. In 2015, Dee Dee was murdered by Gypsy’s then-boyfriend in a crime Gypsy helped plan. The case has since inspired documentaries, television series, podcasts, and an enormous amount of online speculation. But one part of Gypsy’s medical history has received relatively little attention: a chromosomal microdeletion identified through genetic testing. In this special episode drop, we are sharing the fifth installment of “The Gypsy Rose Obsession,” an investigative series from the PRETEND podcast (https://thisispretend.com/) hosted by Javier Leiva. The first four episodes explore the online community that continues to investigate, debate, and develop competing theories about nearly every aspect of Gypsy’s life. We recommend listening to those episodes first for the full context behind the people, records, and claims discussed in this installment. Episode five turns its attention to Gypsy’s reported 1q21.1 microdeletion. DNA Today host and certified genetic counselor Kira Dineen joins Javier as a genetics expert to examine the available records and explain the complexities of interpreting this finding. Kira breaks down chromosomes using a genomic-library analogy, explains how a chromosomal “address” such as 1q21.1 is read, and puts the reported deletion size into perspective. She also compares a traditional karyotype with a chromosomal microarray and explains how a deletion can be too small to detect through one form of testing but identifiable through another. What can the microdeletion tell us about Gypsy’s health? Why might her earlier clinical notes and a later laboratory report describe the finding differently? Could the deletion explain claims involving paralysis, leukemia, or the need for a feeding tube? Most importantly, how do we distinguish a possible genetic association from evidence that a particular finding caused someone’s medical, psychiatric, or behavioral features? This episode discusses medical child abuse, violence, and murder. Please take care while listening. Episode Discussion Topics - What genetic counselors do and how they help patients understand genetic testing - Chromosomes, genes, and microdeletions explained through a genomic-library analogy - How to interpret the chromosomal address “1q21.1” - What it means to have a piece of chromosome 1 missing - Putting the size of the deletion into perspective - Why the size of a genetic change does not always predict its medical impact - The wide spectrum associated with 1q21.1 microdeletions, ranging from no apparent features to developmental and congenital differences - How two people with the same or similar deletion can be affected very differently - Why identifying the deletion does not mean someone will develop every associated condition - Possible developmental, neurological, physical, and behavioral features reported with 1q21.1 microdeletions - The difference between a genetic risk factor and a diagnosis or prediction - Whether paralysis, leukemia, or feeding-tube use are associated with this deletion - Why a genetic finding should not automatically be used to explain every aspect of someone’s medical or behavioral history - The limitations of interpreting genetic information without a complete medical evaluation and family history The information presented in this episode is intended for education and discussion and should not be considered individualized medical advice. Genetic test results should be interpreted by a qualified healthcare professional in the context of the…

    Not rated yet
  • #409 How DNA Testing Exposed the Dark History of American Adoption

    · 43 min

    What happens when stigma, secrecy, and institutional power separate a mother from her child, and prevent an adoptee from accessing his own identity and medical history for decades? This week, we are sharing an episode of DNA Clarity and Support (https://dnaclarityandsupport.podbean.com/), the newest podcast to join the Gene Pool Media network. Host and genetic counselor Brianne Kirkpatrick Williams speaks with New York Times bestselling author and journalist Gabrielle Glaser about her book, American Baby: A Mother, a Child, and the Shadow History of Adoption. American Baby follows Margaret Erle Katz, who became pregnant as a teenager in 1961, and the son she was pressured to relinquish for adoption. That child, later named David Rosenberg, grew up without access to his biological family or family medical history. Decades later, while experiencing serious health problems, David used direct-to-consumer DNA testing to identify his birth family and discovered that the story he had believed about his adoption was not true. Through David and Margaret’s experiences, Gabrielle exposes the coercion, secrecy, and stigma that shaped the postwar adoption industry, and explores why access to original birth records, genetic relatives, and family health history remains so important. On This Episode, We Discuss: - How Gabrielle met David while reporting on his kidney transplant - How DNA testing connected David with his biological family - What David discovered about his birth parents’ efforts to keep him - How sealed adoption records restrict access to identity and family medical history - Stigma, coercion, and secrecy in postwar American adoption - Unethical research conducted on infants awaiting adoption - The emotional complexity of unexpected biological connections and family reunions - Privacy concerns surrounding commercial DNA databases - Support resources for adoptees and others navigating DNA discoveries - Margaret’s journey from decades of secrecy to adoptee-rights advocacy About Gabrielle Glaser Gabrielle Glaser is a New York Times bestselling author and journalist whose work on mental health, medicine, addiction, and culture has appeared in The New York Times Magazine, The New York Times, and many other publications. Her fourth book, American Baby: A Mother, a Child, and the Shadow History of Adoption (https://www.goodreads.com/en/book/show/48710835-american-baby), examines the history of adoption in post–World War II America through the story of one family separated by the country’s secretive and coercive adoption system. Learn more about Gabrielle and her work on herwebsite (https://gabrielleglaser.com/). About Brianne Kirkpatrick Williams Brianne Kirkpatrick Williams is a licensed and certified genetic counselor, genealogist, author, and the founder ofWatershed DNA (https://www.watersheddna.com/). She provides support and guidance for people navigating DNA testing, family searches, adoption, donor conception, misattributed parentage, and unexpected biological relationships. Brianne is also the co-author, with Shannon Combs-Bennett, of The DNA Guide for Adoptees (https://www.goodreads.com/en/book/show/45304776-the-dna-guide-for-adoptees). About DNA Clarity and Support DNA Clarity and Support (https://dnaclarityandsupport.podbean.com/) explores the personal and familial impacts of DNA testing. Brianne speaks with authors, advocates, and leaders about family searches, unexpected discoveries, identity, medical history, and the resources available to people navigating the rapidly changing world of consumer DNA testing. DNA Clarity and Support is produced by Watershed DNA and is part of the Gene Pool Media podcast network (http://genepoolmedia.com). Subscribe wherever you listen to podcasts. Resources - Gabrielle Glaser (https://gabrielleglaser.com/) - American Baby by Gabrielle Glaser (https://www.penguinrandomhouse.com/books/556488/american-baby-by-gabrielle-glaser/?utm_source=chatgpt.com) - The DNA Guide…

    Not rated yet
  • #408 Low ALP, Fractures, and Early Tooth Loss Point to Hypophosphatasia

    · 37 min

    Hypophosphatasia (HPP) can present very differently from one person to the next, from life-threatening complications in infancy to fractures, chronic pain, muscle weakness, or early tooth loss later in life. With symptoms spanning multiple body systems and varying across the lifespan, how can clinicians recognize when these seemingly disconnected findings may point to HPP? In the first episode of our three-part series on hypophosphatasia, we are joined by genetic counselor Amy Patterson to explore the clinical spectrum and diagnosis of HPP. Amy explains what happens biologically in HPP, why traditional age-based classifications do not always capture its variability, and how the condition may present from the prenatal period through adulthood. We also discuss the importance of persistently low alkaline phosphatase (ALP), including why results must be interpreted using age- and sex-appropriate reference ranges. Amy reviews the additional laboratory findings, medical and dental histories, imaging, physical examination, and molecular testing that may contribute to a diagnosis. She also highlights common misdiagnoses and the clinical clues that should prompt healthcare providers to consider HPP. Episode Discussion Topics - What hypophosphatasia is and how impaired mineralization affects the body - The perinatal, infantile, childhood, adult, and odonto forms of HPP - Prenatal and infantile presentations of severe HPP - Clinical and dental signs in children - Fractures, chronic pain, fatigue, weakness, and dental concerns in adults - How manifestations may change throughout a person’s lifetime - Variability among relatives with the same familial ALPL variants - Common diagnostic delays and misdiagnoses - Distinguishing HPP from other causes of rickets and skeletal abnormalities - Differentiating HPP from osteoporosis, osteopenia, osteoarthritis, and fibromyalgia - The importance of persistently low ALP and appropriate reference ranges - Alternative explanations for a low ALP result - The HPP International Working Group - The roles of laboratory testing, radiographs, dental records, and medical history - When molecular testing of the ALPL gene may be appropriate - Whether HPP can be diagnosed without an identified pathogenic or likely pathogenic ALPL variant About the Guest Amy Patterson (https://www.linkedin.com/in/amympatterson/), MS, CGC, is a licensed, board-certified genetic counselor in the Department of Genetic Medicine at Johns Hopkins. She works with pediatric and adult patients in the general genetics clinic and the Greenberg Center for Skeletal Dysplasias, including individuals and families affected by hypophosphatasia. About the Series This episode is the first in a three-part educational series about hypophosphatasia. Stay tuned for the next installment . Across the series, we explore the clinical spectrum and diagnosis of HPP, its genetic basis and variable expression, and considerations for genetic counseling and management. This series is sponsored by Alexion. The views expressed by the host and guests are their own. Resources - Dahir KM, Nunes ME.Hypophosphatasia (https://www.ncbi.nlm.nih.gov/books/NBK1150/). GeneReviews®. Updated March 27, 2025. This comprehensive clinical overview covers the presentation, diagnosis, genetics, management, and genetic counseling considerations for HPP. - Beck NM, Sagaser KG, Lawson CS, et al.Not just a carrier: Clinical presentation and management of patients with heterozygous disease-causing alkaline phosphatase (ALPL) variants identified through expanded carrier screening (https://pubmed.ncbi.nlm.nih.gov/36444396/). Molecular Genetics & Genomic Medicine. 2023;11(1):e2056. - Khan AA, Brandi ML, Rush ET, et al.Hypophosphatasia diagnosis: Current state of the art and proposed diagnostic criteria for children and adults (https://pubmed.ncbi.nlm.nih.gov/37982857/). Osteoporosis International. 2024;35(3):431–438. - Rush E, Brandi ML, Khan A, et al.Proposed…

    Not rated yet
  • #407 NFL and Kansas City Chiefs Star Art Still on the Missed Signs of Hereditary Amyloidosis

    · 39 min

    What happens when the symptoms of a genetic condition look like the lasting effects of a professional football career? Former NFL defensive end and Kansas City Chiefs star Art Still spent decades attributing carpal tunnel syndrome, trigger finger, back problems, joint and tendon injuries, neuropathy, and other health concerns to football, aging, and ordinary wear and tear. Even when he developed atrial fibrillation, Art’s lifelong discipline and athlete mentality made him believe he could manage his health on his own. Art and his wife, Liz Still, join host Kira Dineen to share how those seemingly disconnected symptoms were eventually traced to hereditary transthyretin amyloidosis, also known as hereditary ATTR or hATTR amyloidosis. During evaluations through the NFL Player Care Foundation wellness program, Art’s healthcare providers looked beyond his individual symptoms and asked about his family health history. That conversation revealed a striking pattern: relatives with serious cardiac, neurologic, and mobility-related conditions, including Art’s older brother, who received a heart transplant, and his nephew, who lived with sickle cell disease and had previously tested positive for the same TTR variant. Genetic testing confirmed that Art carries the V122I variant, also called p.Val142Ile or V142I, in the TTR gene. This variant is found in approximately 3–4% of Black Americans, or about 1 in 25, although carrying it does not necessarily mean someone will develop amyloidosis. For Art and Liz, the diagnosis provided answers, but it also raised questions for their 11 children, 28th grandchild on the way, and extended family. They discuss navigating family conversations about inherited health risks, the value of genetic testing, Art’s evolving trust in healthcare, and why following a treatment plan matters. Through their nonprofit,Still 4 Life (https://still4life.org/), Art and Liz now offer free community presentations focused on awareness, earlier detection, family health history, and self-advocacy. Their goal is to make complicated medical information easier to understand and reach people who may otherwise dismiss their symptoms or hesitate to seek care. Episode Discussion Topics - How Art’s “no pain, no gain” athlete mentality shaped his response to symptoms - Why professional athletes may normalize pain and avoid disclosing injuries - The symptoms Art initially attributed to football, including carpal tunnel syndrome, trigger finger, back problems, neuropathy, joint and tendon injuries, and a torn biceps - Why a torn biceps can be a potential warning sign of transthyretin amyloidosis - Liz’s early belief that Art’s symptoms were natural consequences of his football career - When Art’s cardiac symptoms caused Liz to realize something else might be happening - Art’s history of atrial fibrillation and his initial resistance to medication - His evaluations through the NFL Player Care Foundation wellness program - The family health history questions that helped connect Art’s seemingly unrelated symptoms - His brother’s heart transplant - His nephew’s sickle cell disease, amyloidosis, and earlier genetic test result - Why Art’s nephew was originally evaluated for Marfan syndrome - How genetic testing identified Art’s V122I TTR variant - The relief of finally understanding the cause of Art’s health problems - How the diagnosis changed conversations with their 11 children and extended family - Why family health history may be one of the most valuable legacies a family can preserve - The difference between carrying a genetic variant and developing symptoms - Why ancestry can help identify risk but should not be used to exclude someone from consideration - Art’s mistrust of the medical and pharmaceutical industries, and how his perspective evolved - What happened when Art reduced and stopped his heart medication without medical guidance - Why finding a healthcare team that explains the purpose of treatment…

    Not rated yet
  • #406 Mock Teratogen Genetic Counseling Session: Ozempic, Zoloft, Xanax, and Metformin

    · 30 min

    This is our seventh installment in our Mock Genetic Counseling Session Series! In this episode, genetic counselor and teratogen information specialist Sharon Voyer Lavigne and student Edith Atwerebour perform a mock genetic counseling session. The session indication is medication exposures during pregnancy, including Ozempic®, metformin, Zoloft®, and Xanax®. This session was recorded in person, providing a more dynamic and engaging learning experience. Therefore, we highly recommend watching it on YouTube to fully immerse yourself in the interaction. We hope this series is helpful for prospective and current genetic counseling students, as well as the general public, by demystifying the genetic counseling process. The Actors: Edith Atwerebour is currently a student in the Human Genetics Program at Sarah Lawrence College training to become a genetic counselor. In this mock session, she plays Denise, a 34-year-old woman who is pregnant with her second child and seeking information about medication exposures during pregnancy. The premise of this mock case was developed as part of Atwerebour’s internship with DNA Today. Sharon Voyer Lavigne (https://mothertobaby.org/team/?utm_source=chatgpt.com), MS, LGC, is a licensed genetic counselor, teratogen information specialist, and Coordinator of MotherToBaby Connecticut. She has worked with MotherToBaby Connecticut for more than 28 years and also serves as its Research Coordinator. Lavigne is a Clinical Instructor in the Division of Human Genetics within the Department of Genetics and Genome Sciences at UConn Health. She teaches and trains genetic counseling students, maternal-fetal medicine fellows, OB/GYN residents, and other healthcare professionals. Lavigne received her Bachelor of Science in Biology from Northeastern University and her Master of Science in Human Genetics/Genetic Counseling from Sarah Lawrence College. Through MotherToBaby, she helps patients and healthcare professionals understand the most current evidence about medications and other exposures during pregnancy and breastfeeding. Mock Session Overview: - How genetic counselors establish the approximately 3% background risk for birth defects before discussing specific exposures - Why the timing, dose, frequency, and duration of a medication exposure matter - What is currently known, and still unknown, about semaglutide (Ozempic®/Wegovy®) exposure during early pregnancy - Why controlling type 2 diabetes may be more important than the medication exposure itself - The role of metformin, insulin, maternal-fetal medicine specialists, and diabetes educators during pregnancy - What research suggests about sertraline (Zoloft®) use and the risk for structural birth defects - How untreated anxiety and depression can also affect maternal and pregnancy health - Possible newborn adaptation symptoms following exposure to certain psychiatric medications - Why patients should consult their healthcare providers before reducing or discontinuing medication - How therapy, family support, and postpartum planning can complement medication management - The role of anatomy ultrasounds and fetal echocardiograms in pregnancy monitoring - How MotherToBaby helps patients and healthcare providers navigate exposures during pregnancy and breastfeeding The central takeaway from the session is that Denise’s reported medication exposures are not expected to place the pregnancy at a significantly greater overall risk. Instead, the primary priorities are improving diabetes control, maintaining her mental health, and coordinating care among her obstetrician and other healthcare providers. MotherToBaby Resources: MotherToBaby (https://mothertobaby.org/) provides free, evidence-based information about medications and other exposures during pregnancy and breastfeeding. Patients and healthcare providers can contact MotherToBaby by phone, text, email, or live chat. MotherToBaby Pregnancy and Breastfeeding Fact Sheets…

    Not rated yet
  • #405 Why Insurance Denies Genetic Testing, and How to Navigate Coverage

    · 34 min

    Genetic testing can change the course of a patient’s care, but accessing the right test is not always straightforward. Behind the scenes, insurance coverage decisions, documentation requirements, prior authorization, denials, appeals, and cost concerns can all influence whether a patient receives timely answers. In this episode of DNA Today, we launch a new special series sponsored by Revvity (https://www.revvity.com/) in this episode exploring the health economics of genetic testing and the real-world systems that shape access to genomic medicine. Host Kira Dineen is joined by Dr. Madhuri Hegde, Senior Vice President and Chief Scientific Officer at Revvity, and Mackenzie Mosera Derby, a pediatric genetic counselor at UW Health. Together, they examine genetic testing access from both the diagnostic laboratory and clinical perspectives exploring why insurance coverage remains so inconsistent, what goes into a prior authorization, why genetic tests are commonly denied, and how clinicians can approach appeals and peer-to-peer reviews. In This Episode, We Discuss - The transition from stacked laboratory procedure codes to codes for genes, panels, exomes, and genomes - How and why insurance coverage varies among payers and individual health plans - Coverage differences across hereditary cancer testing, exome sequencing, genome sequencing, reproductive testing, and population screening - How rapid and ultra-rapid genome sequencing may be covered differently from standard genome sequencing - The limited coverage available for preventive and population-based genomic testing - The coordination required among patients, clinicians, laboratories, and insurance companies - Why laboratories offering tests with similar names may differ in technology, interpretation, turnaround time, and clinical support - What documentation is typically required for a genetic testing prior authorization - How clinicians demonstrate medical necessity and clinical utility - Why professional guidelines and peer-reviewed literature can strengthen an authorization request - The role laboratories play in benefits investigations, billing assistance, financial support, and prior authorization - Why laboratories may perform testing without knowing whether they will ultimately be reimbursed - Common reasons insurance companies deny genetic testing - Why “this test will not change clinical management” can be an overly narrow interpretation of genetic testing’s value - How genetic results may inform surveillance, reproductive decisions, recurrence risks, family members, research eligibility, and patient support - The role of hospital test utilization committees - Why genetic counselors and geneticists should be represented on utilization review teams - How letters of medical necessity (LOMN) and peer-to-peer reviews may support an appeal - Why genetic counselors may be prevented from conducting peer-to-peer reviews, even when they were the ordering provider - The time clinicians spend educating insurance representatives about genetics - Why payer policies frequently lag behind genomic technology and professional recommendations - The importance of detailed clinical documentation and accurate diagnostic coding - The difference between prior authorization, insurance coverage, and guaranteed payment - How self-pay pricing and misleading “no-cost” language can create confusion - The potential devaluation of genetic testing and genetic counseling services through complementary or low cost self-pay options - Why improving access requires collaboration among patients, clinicians, laboratories, professional organizations, healthcare systems, and payers About The Guests Madhuri Hegde (https://www.revvity.com/meet-our-revvity-omics-global-experts), PhD, FACMG, is the Senior Vice President and Chief Scientific Officer at Revvity, where she leads the company’s scientific strategy and oversees Revvity Omics’ global network of laboratories. Dr. Hegde…

    Not rated yet
  • #404 Male Breast Cancer with X-Men Actor and Former Pro Wrestler Tyler Mane

    · 21 min

    What happens when someone known for strength, stature, and intimidating roles faces a diagnosis most people do not associate with men? Tyler Mane is known for playing Sabretooth in X-Men and Deadpool & Wolverine, Michael Myers in Halloween, and Ajax in Troy. Before his acting career, Tyler spent more than a decade wrestling professionally around the world, including appearances with WCW and UWF as Big Sky and Nitron. Recently, Tyler has taken on a very different role: raising awareness about male breast cancer. Tyler joins host Kira Dineen to share his experience of discovering a breast lump, initially believing it was a lipoma, having his concerns dismissed, and ultimately receiving a breast cancer diagnosis. He opens up about his first instinct to keep the diagnosis private, the embarrassment he initially felt, and what motivated him to speak publicly. Episode Discussion Topics - The breast lump that led Tyler to seek medical care - Why Tyler and his wife, Renae, initially believed the lump was a lipoma - Having his concerns dismissed and continuing to pursue answers - Tyler’s first reaction to his breast cancer diagnosis - The embarrassment and stigma surrounding male breast cancer - Why he ultimately decided to share his story publicly - Symptoms and physical changes men should pay attention to - How masculinity and “toughing it out” can delay medical care - The importance of self-advocacy and early detection - How cancer treatment differs from the physical demands of wrestling - Redefining strength during illness and recovery - Genetic counseling and germline genetic testing after a male breast cancer diagnosis - The implications of Tyler’s BRCA2+ genetic testing results for treatment and relatives including his adult children - How Tyler’s public image affects the response to his diagnosis - Tyler and Renae’s upcoming podcast, MANE AF Resources & Links - Tyler Mane’s Breast Cancer Announcement Instagram Video (https://www.instagram.com/p/DZVXUN2xWW0/) - @TheRealTylerMane (https://www.instagram.com/therealtylermane/) - @ManeAFpod (https://www.instagram.com/maneafpod/) - NCCN Patient Resources for Breast Cancer (https://www.nccn.org/patientresources/patient-resources/guidelines-for-patients/breast-cancer-resources) - NCCN patient resources are based on the same treatment information your doctors use and help you talk to your doctor about the best treatment options for your disease. - National Cancer Institute: Breast Cancer in Men (https://www.cancer.gov/types/breast/male-breast-cancer) - The National Cancer Institute provides an overview of male breast cancer symptoms, diagnosis, treatment, genetic testing, and questions patients may want to discuss with their healthcare teams. The NCI notes that inherited variants in BRCA1, BRCA2, and other genes may influence treatment and have implications for relatives. - Facing Our Risk of Cancer Empowered (FORCE) (http://facingourrisk.org) - FORCE provides education, peer support, advocacy, research updates, and resources for people and families affected by inherited cancer risk, including BRCA1, BRCA2, PALB2, ATM, CHEK2, and other genes. - Find a Genetic Counselor (https://findageneticcounselor.nsgc.org/) - The National Society of Genetic Counselors’ (NSGC) directory can help patients locate a genetic counselor specializing in cancer genetics, either locally or through telehealth. - Cancer Genetic Testing (https://www.cancer.org/cancer/risk-prevention/genetics/genetic-testing-for-cancer-risk.html) - Genetic testing panels vary with how many genes are included. Healthcare providers can order just one gene or around a hundred, and everything in between. Tyler mentioned his possibly including 85, which is plausible. Relevant DNA Today Podcast Episode - #360 Hereditary Breast Cancer on the Big Screen with Love, Danielle (https://dnapodcast.com/episodes/2025/9/26/360-hereditary-breast-cancer-on-the-big-screen-with-love-danielle) - Actress and filmmaker Devin…

    Not rated yet
  • #403 Genetic Counseling Boards Prep: ABGC’s New Resources

    · 30 min

    Preparing for the genetic counseling board exam can feel overwhelming. Between the extensive study materials, challenging practice questions, and uncertainty about what to expect on exam day, candidates often struggle to determine where to begin and how to use their preparation time effectively. In this episode of DNA Today, host Kira Dineen is joined by Melanie Hardy and Amy Shikany to explore the new and updated resources available to candidates preparing for the American Board of Genetic Counseling (ABGC) Certification Examination. Melanie Hardy is the 2026 President of ABGC, and Amy Shikany is ABGC President-Elect and a past Chair of the Certification and Education Committee. Together, they discuss ABGC’s Certify webpage, the new CGC self-study guide, the approved references list, a new student webinar, and the updated practice examination that launched on June 15, 2026. They also take listeners behind the scenes of how the certification exam is developed, reviewed, and maintained. Discussion Topics: - What the ABGC Certification Examination is designed to assess - Where candidates should begin when navigating ABGC’s certification and exam resources - How to use the exam content outline when developing a study plan - Why ABGC created its new CGC self-study guide - How candidates can use the self-study guide alongside the approved references - What candidates can expect from ABGC’s new student webinar - How questions for the certification exam are written and reviewed - What makes a strong “one best answer” board-exam question - How ABGC evaluates questions for accuracy, relevance, fairness, and justice, equity, diversity, and inclusion considerations - What has changed in the updated ABGC practice examination - How closely the practice exam reflects the structure and reasoning required on the certification exam - How candidates should interpret their practice-exam results - How the passing standard for the certification exam is determined - Preparation steps candidates should take before exam day - Encouragement and next steps for candidates who do not pass on their first attempt - How certified genetic counselors can contribute to the development and maintenance of the examination One clarification from the conversation: candidates are provided access to a simple calculator during the certification exam. About the Guests Melanie Hardy (https://www.linkedin.com/in/mwhardy47/), MS, CGC is the 2026 President of the American Board of Genetic Counseling. Through her leadership with ABGC, she supports the organization’s work to establish and maintain certification standards for the genetic counseling profession and provide resources for current and future certified genetic counselors. Amy Shikany (https://www.linkedin.com/in/amy-shikany-20958871/), MS, CGC is President-Elect of the American Board of Genetic Counseling and a past Chair of ABGC’s Certification and Education Committee. Her work with ABGC has included supporting the development, review, and ongoing maintenance of the genetic counseling certification examination. Resources Mentioned - American Board of Genetic Counseling (ABGC) website (https://www.abgc.net/) - Introducing the New CGC® Logo & Digital Badge (https://www.linkedin.com/posts/abgcertifiedgcs_now-introducing-abgc-is-proud-to-launch-activity-7480984230626254848-nO4l/) - ABGC Certify - Eligibility Requirements (https://www.abgc.net/Certify/Eligibility-Requirements) - Certification Process, Exam and Fees (https://www.abgc.net/Certify/Certification-Process-Exam-and-Fees) - Need-Based Certification Scholarship (https://www.abgc.net/Certify/Need-Based-Certification-Scholarship) - ABGC CGC Exam Resources - Candidate Guide (Start here) (https://www.abgc.net/Portals/0/Guides/ABGC_Candidate-Guide_2025_Final.pdf) - Exam Content Outline (https://www.abgc.net/Portals/0/2023%20CGC%20Exam%20Content%20Outline.pdf?ver=ELvyidDNqixxIF8lTpWWWQ%3D%3D) - Self Study Guide…

    Not rated yet
  • #402 How Genetic Genealogy Caught the Golden State Killer

    · 24 min

    What happens when DNA from a decades-old crime scene meets a family tree created generations later? That combination helped investigators identify the Golden State Killer and transformed how law enforcement approaches some of the country’s most difficult cold cases. Content warning: This episode includes discussions of murder, sexual assault, suicide, and other sensitive topics. In this episode of DNA Today, host Kira Dineen speaks with Paul Holes, a retired cold-case investigator, New York Times bestselling author, podcaster, and television host. During his 27-year career with the Contra Costa County Sheriff’s and District Attorney’s Offices, Paul worked on some of the most infamous cases in American criminal history, including the Zodiac murders, the kidnapping of Jaycee Dugard, and the investigation that ultimately identified Joseph DeAngelo as the Golden State Killer. Paul is also the author of Unmasked: My Life Solving America’s Cold Cases, co-host of the podcast Small Town Dicks, and one of the investigators featured in the television special Celebrity Crime Scene: Marilyn Monroe, available on Hulu. We explore the science, strategy, and ethical complexity behind cold-case investigations. Paul shares how investigators determine whether decades-old evidence still holds value, what kind of DNA evidence would be needed to scientifically resolve the Zodiac case, and why older biological samples create difficult decisions about whether to test now or preserve evidence for future technologies. The episode also dives into the landmark investigation that identified the Golden State Killer. Paul walks through how traditional forensic DNA databases failed to produce a match, why investigative genetic genealogy changed the direction of the case, and how distant relatives’ DNA helped investigators build family trees that eventually led to Joseph DeAngelo. Later in the episode, Paul discusses his latest project, Celebrity Crime Scene: Marilyn Monroe, and how modern virtual reconstruction can be used to reexamine a historic death scene more than six decades later. Episode Discussion Topics - Cold-case investigations and how evidence is reexamined decades later - How investigators decide which biological samples may still have forensic value - The Zodiac Killer case and what would be needed to consider it scientifically solved - The challenges of DNA evidence from stamps, envelopes, letters, and other handled items - Why finite evidence creates difficult decisions about testing now versus waiting for future technology - The role of DNA in linking the Golden State Killer crimes before a suspect was identified - Why traditional forensic DNA databases did not solve the case - How investigative genetic genealogy helped generate a new lead - How distant relatives’ DNA can help identify someone who never uploaded their own DNA - The scientific and investigative process behind building genealogical trees from crime-scene DNA - How investigators narrowed family branches until Joseph DeAngelo became a viable suspect - Reconstructing Marilyn Monroe’s final hours using virtual crime-scene technology - What records, photographs, reports, and witness statements can reveal in historical case reviews About Paul Holes Paul Holes is a retired cold-case investigator, New York Times bestselling author, podcaster, and television host. During his 27-year career with the Contra Costa County Sheriff’s and District Attorney’s Offices, he investigated some of the country’s most complex and high-profile cases, including the Zodiac murders, the kidnapping of Jaycee Dugard, and the Golden State Killer case. Paul’s work helped bring national attention to the power of investigative genetic genealogy, particularly through the identification of Joseph DeAngelo as the Golden State Killer. He is the author of Unmasked: My Life Solving America’s Cold Cases, co-host of Small Town Dicks, and appears in Celebrity Crime Scene: Marilyn Monroe.…

    Not rated yet
  • #401 The First Precision Medicine for Achondroplasia with Dr. Ravi Savarirayan

    · 36 min

    Just a few years ago, there were no pharmacological treatments for patients with achondroplasia. Today, with multiple therapies on the market, the conversation has shifted from if we can treat to how we treat safely, consistently, and thoughtfully. In this third and final installment of our achondroplasia series, sponsored by BioMarin, we explore the recently published international consensus guidelines for vosoritide. These guidelines provide a roadmap for the entire treatment lifecycle, from the initial diagnosis and counseling to initiation, monitoring, and eventually, the transition off therapy. You can review the prescribing information for vosoritide here (https://hcp.biomarin.com/en-us/voxzogo/administering-voxzogo/?utm_source=google&utm_medium=paidsearch&utm_campaign=20260105_mrge_sc_bmv_ach_protect-br-hcp_hcp_pa_aw_us_ctwd_en_nk&utm_content=brand-hcp-branded-vos-treatment&gad_source=1&gad_campaignid=22546758435&gbraid=0AAAAABzCk9VhIPtJtm1zM3zWYfCAHav4l&gclid=Cj0KCQjw2_TQBhCnARIsAF3-XhwJDNZV1i9pT6pzJvSSDZXknLFOxAQ_oisvA_rOZdBUoHX0_TNFXXsaAup1EALw_wcB) with additional safety information, including about the risk of low blood pressure. Joining us in-person all the way from Australia is the lead author of these guidelines, Dr. Ravi Savarirayan. Dr. Savarirayan is a global leader in skeletal dysplasia and has been a driving force in the clinical development of vosoritide from its earliest stages. Topics Discuss: The Journey of Vosoritide: Dr. Savarirayan shares his personal "why", from the early research phases to the clinical trials that changed the landscape of skeletal dysplasia care. Precision Medicine at the Molecular Level: How vosoritide acts as the first precision medicine approved for achondroplasia by targeting and counteracting overactive FGFR3 signaling, along with important safety information such as a risk for low blood pressure The International Guidelines: Why a global consensus was necessary and how it addresses gaps in real-world clinical practice. The Treatment Lifecycle: - Counseling: Setting expectations and having the first conversation with families. - Initiation: Practical tips for daily subcutaneous injections and establishing a routine. - Safety & Monitoring: How clinicians monitor growth and manage safety considerations like hypotension across different age groups. - Discontinuation: How to navigate growth plate closure and the transition off therapy. The Future of Care: How these guidelines will evolve as we gather more long-term, real-world data. Our Guest Dr. Ravi Savarirayan: Ravi Savarirayan is consultant clinical geneticist at Victorian Clinical Genetics Services, Professorial fellow at the University of Melbourne, and Group leader (Molecular Therapies at Murdoch Children’s Research Institute, Victoria, Australia. Professor Savarirayan received his MBBS from the University of Adelaide, Australia in 1990 and became a Fellow of the Royal Australasian College of Physicians in 1997. He was certified as a specialist in Clinical Genetics by the Human Genetics Society of Australasia in 1998 and was awarded his Doctor of Medicine from the University of Melbourne in 2004. He was awarded the Fulbright Professional Scholarship for Australia in 1998, and took this up at University of California, Los Angeles (UCLA). Professor Savarirayan’s primary research focus is on inherited disorders of the skeleton causing short stature, arthritis, and osteoporosis. He has published over 230 peer-reviewed articles and received over $35M in research funding, collaborating with researchers from 40 countries. His current clinical trial activities are pioneering disruptive new therapies for the treatment of genetic disorders. He was the global lead investigator of the clinical development program that identified vosoritide as the first precision therapy for children with achondroplasia. He was recently named one of the 30 “Brilliant minds” of the Murdoch Children’s Research Institute over the past 30…

    Not rated yet